Fosicard 5 mg tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

fosicard 5 mg tablete

actavis group ptc ehf. - fozinopril - tableta - fozinopril 4,8 mg / 1 tableta - fozinopril

Olinapril - H 20 mg/12,5 mg tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

olinapril - h 20 mg/12,5 mg tablete

lek d.d. - enalaprilijev maleat; hidroklorotiazid - tableta - enalaprilijev maleat 20 mg / 1 tableta  hidroklorotiazid12,5 mg / 1 tableta; hidroklorotiazid 12,5 mg / 1 tableta - enalapril in diuretiki

Olinapril - H 20 mg/12,5 mg tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

olinapril - h 20 mg/12,5 mg tablete

lek d.d. - enalaprilijev maleat; hidroklorotiazid - tableta - enalaprilijev maleat 20 mg / 1 tableta  hidroklorotiazid12,5 mg / 1 tableta; hidroklorotiazid 12,5 mg / 1 tableta - enalapril in diuretiki

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Evropska unija - slovenščina - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - klopidogrel besilat - peripheral vascular diseases; stroke; myocardial infarction - antitrombotična sredstva - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st segmentu višinskih akutni miokardni infarkt, v kombinaciji s asa v medicinsko zdravljenih bolnikih, ki izpolnjujejo pogoje za thrombolytic terapija. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. za nadaljnje informacije, prosimo, preberite razdelek 5.

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Evropska unija - slovenščina - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotična sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Doksivibra 100 mg disperzibilne tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

doksivibra 100 mg disperzibilne tablete

pfizer luxembourg sarl - doksiciklin - disperzibilna tableta - doksiciklin 100 mg / 1 tableta - doksiciklin

Zypsila 20 mg trde kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

zypsila 20 mg trde kapsule

krka, d.d., novo mesto - ziprasidon - kapsula, trda - ziprasidon 20 mg / 1 kapsula - ziprasidon

Zypsila 20 mg trde kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

zypsila 20 mg trde kapsule

krka, d.d., novo mesto - ziprasidon - kapsula, trda - ziprasidon 20 mg / 1 kapsula - ziprasidon

Zypsila 20 mg trde kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

zypsila 20 mg trde kapsule

krka, d.d., novo mesto - ziprasidon - kapsula, trda - ziprasidon 20 mg / 1 kapsula - ziprasidon

Zypsila 40 mg trde kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

zypsila 40 mg trde kapsule

krka, d.d., novo mesto - ziprasidon - kapsula, trda - ziprasidon 40 mg / 1 kapsula - ziprasidon